Abcam, ab308464, Anti-CPLX3 antibody [EPR28433-43] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CPLX3 antibody. Carrier free. Suitable for WB, IHC-P, IHC-Fr, IP, mIHC and reacts with Transfected cell lysate - Mouse, Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28433-43,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:IP, WB, mIHC, IHC-P, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Unsuitable for rat IHC-Fr.ab308463 shows weak cross reactivity with  Complexin-4.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CPLX3 also known as Complexin-3 is a small synaptic protein with a molecular weight of approximately 18 kDa. It is expressed abundantly in the brain specifically in sensory-related areas where it acts at the presynaptic terminal. CPLX3 belongs to the complexin family which includes Complexin-1 Complexin-2 and Complexin-4. Its expression patterns suggest a role in the central nervous system (CNS) in neurons associated with sensory processing.
Biological function summary
Complexin-3 participates in synaptic vesicle exocytosis by binding to the SNARE complex. This interaction helps regulate the release of neurotransmitters which is essential for proper synaptic function. CPLX3 plays a part in the synaptic vesicle cycle and ensures the precise timing of neurotransmitter release. It may also modulate synaptic plasticity which influences learning and memory processes in the CNS.
Pathways
Complexin-3 operates within the synaptic vesicle cycle and neurotransmitter release pathways. It collaborates closely with SNARE proteins like Syntaxin and Synaptobrevin both key for membrane fusion and neurotransmitter release. CPLX3 fine-tunes these processes impacting the efficiency and dynamics of synaptic transmission. Its function in these pathways highlights its relevance in regulating synaptic communication and plasticity.
Complexin-3 has been implicated in neurological conditions such as schizophrenia and autism spectrum disorders. Altered expression levels of CPLX3 may disrupt synaptic signaling contributing to the pathophysiology of these conditions. Its interaction with SNARE proteins underlies its potential involvement in these disorders. Understanding CPLX3's role in these diseases can inform therapeutic strategies for managing synaptic dysfunctions associated with neurological conditions.